Drug Profile

MIN 101 - Minoryx Therapeutics

Alternative Names: MIN-101 Minoryx Therapeutics

Latest Information Update: 25 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IDIBELL
Developer IDIBELL; Minoryx Therapeutics
Class Small molecules; Thiazolidinediones
Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Adrenoleucodystrophy
New Molecular Entity No

Highest Development Phases

Discontinued Adrenoleucodystrophy

Most Recent Events

04 Jan 2017 Discontinued - Preclinical for Adrenoleucodystrophy in Spain (PO) (Minoryx Therapeutics pipeline, January 2017)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com